Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

M.V. Dieci, N. Radosevic-Robin, S. Fineberg, G. van den Eynden, N. Ternes, F. Penault-Llorca, G. Pruneri, T.M. D'Alfonso, S. Demaria, C. Castaneda, J. Sanchez, S. Badve, S. Michiels, V. Bossuyt, F. Rojo, B. Singh, T. Nielsen, G. Viale, S.-R. Kim, S. HewittS. Wienert, S. Loibl, D. Rimm, F. Symmans, C. Denkert, S. Adams, S. Loi, R. Salgado, on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Research output: Contribution to journalArticlepeer-review

Cite this